DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Kuter I, Hegg R, Singer C. et al
Fulvestrant 500 mg vs. 250 mg: first results from NEWEST, a randomized, phase II neoadjuvant trial in postmenopausal women with locally advanced, estrogen receptor-positive breast cancer.
Breast Cancer Res Treat 2007; 106 (Suppl.): S7-
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.